1. Home
  2. FRVO vs TGTX Comparison

FRVO vs TGTX Comparison

Compare FRVO & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FRVO

Fervo Energy Company Class A common stock

N/A

Current Price

$11.13

Market Cap

10.0B

Sector

Utilities

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$64.85

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FRVO
TGTX
Founded
2017
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0B
8.5B
IPO Year
2026
2008

Fundamental Metrics

Financial Performance
Metric
FRVO
TGTX
Price
$11.13
$64.85
Analyst Decision
Strong Buy
Buy
Analyst Count
16
8
Target Price
$29.47
★ $69.43
AVG Volume (30 Days)
★ 8.2M
1.8M
Earning Date
11-09-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 1746.67
EPS
N/A
★ 0.52
Revenue
N/A
★ $2,785,000.00
Revenue This Year
$4,370.99
$61.95
Revenue Next Year
$1,058.41
$35.55
P/E Ratio
★ N/A
$121.69
Revenue Growth
★ N/A
N/A
52 Week Low
$7.64
$26.76
52 Week High
$41.42
$68.03

Technical Indicators

Market Signals
Indicator
FRVO
TGTX
Relative Strength Index (RSI) 51.55 61.88
Support Level $7.68 $52.12
Resistance Level $13.28 $68.03
Average True Range (ATR) 1.13 3.58
MACD 0.40 0.25
Stochastic Oscillator 63.15 76.24

Price Performance

Historical Comparison
FRVO
TGTX

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: